Global pharmaceutical company Pfizer (NYSE: PFE) reported revenue ahead of Wall Street’s expectations in Q3 2026, but sales were flat year on year at $16.58 billion. The company’s full-year revenue guidance of $63 billion at the midpoint came in 1.2% above analysts’ estimates. Its non-GAAP profit of $0.87 per share was 19.3% above analysts’ consensus estimates.

Is now the time to buy PFE? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Pfizer’s third quarter was highlighted by steady commercial execution across its core portfolio, with non-COVID products driving operational revenue growth. Management pointed to robust performance in recently launched and acquired assets, notably Padcev, Nurtec, and Lorbrena, which offset declines in legacy products. CEO Albert Bourla credited “excellent commercial execution” and the integration of Seagen’s oncology medicines as central to the quarter’s momentum. Despite an overall flat revenue line year-over-year, the company benefited from continued productivity improvements and disciplined cost management, supporting investment in its research pipeline.

Looking ahead, Pfizer’s raised full-year guidance is anchored by expectations for continued expansion of its oncology, obesity, and neurology franchises. Management plans to advance ten phase III trials in obesity and sees a global opportunity for its GLP-1 therapy, berobenatide. CFO Cecile Guegan emphasized ongoing cost discipline and a commitment to delivering nearly all of the anticipated $7.2 billion in net savings by the end of 2026. As Bourla stated, “Our late-stage pipeline progress, with a significant number of pivotal readouts expected near term, is strengthening our opportunity to extend our leadership in key areas.”

Key insights from management’s remarks

Pfizer’s management highlighted strong contributions from newly acquired products and a disciplined approach to cost controls as primary factors shaping Q3 results and supporting improved guidance.

• Acquired portfolio drives growth: The combined contribution of Seagen, Metsera, and Biohaven products delivered 32% operational growth, with Padcev’s U.S. performance and Nurtec’s international expansion leading the way.
• Oncology pipeline expansion: Integration of Seagen doubled Pfizer’s early-stage oncology pipeline, with late-stage programs in multiple myeloma, breast cancer, and lung cancer progressing rapidly and setting up future launches.
• Obesity franchise momentum: The pipeline saw significant enrollment progress in phase IIb and III studies for berobenatide, Pfizer’s monthly GLP-1 candidate, and amylin combination therapies, with an initial approval target in 2028.
• Cost discipline and savings: The ongoing productivity initiatives are on track for the targeted $7.2 billion in net savings by end of 2026, with an additional $2.5 billion planned through 2029, helping offset margin pressures from loss of exclusivity (LOE).
• AI and digital transformation: The launch of the GENESIS AI pharmacovigilance platform is streamlining global safety monitoring, freeing up scientific resources and aiming to accelerate R&D and commercialization efficiency.

Drivers of future performance

Pfizer’s outlook hinges on ramping its new product franchises, achieving targeted cost savings, and progressing key late-stage trials.

• New launches and pipeline catalysts: Future performance will be driven by broader adoption of products like Padcev, Nurtec, and Lorbrena, as well as upcoming readouts from pivotal studies in oncology, obesity (berobenatide), and immunology. Management expects these assets to help counteract revenue erosion from LOE events affecting older drugs.
• Margin management and cost control: The company’s forecast assumes successful execution of its cost improvement programs, targeting $7.2 billion in savings by 2026 and an additional $2.5 billion through 2029. These initiatives will be critical for maintaining profitability as R&D investments increase and LOE pressures mount.
• Regulatory and reimbursement dynamics: Management cited potential headwinds from U.S. drug price reforms (IRA, MFN rules), international pricing changes, and competition in crowded categories. The ability to secure favorable market access and reimbursement for new launches—especially in obesity and oncology—remains an important variable.

Catalysts in upcoming quarters

In the coming quarters, our analysts will be watching (1) pivotal phase III trial readouts for berobenatide and key oncology candidates, (2) evidence of successful cost savings as Pfizer manages through major LOE events, and (3) regulatory progress for Lyme disease and expanded GLP-1 indications. Execution in these areas and commercial uptake of newly launched products will be critical signposts for long-term growth.

Pfizer currently trades at $30.11, down from $30.82 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

Our favorite stocks right now

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.